March 17th 2025
This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization
February 6th 2020Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.
Catalent, Ethicann Partner on Fast-Dissolve Cannabinoid Treatment for MS Spasticity
December 5th 2019Catalent and Ethicann Pharmaceuticals have announced a partnership aimed at developing a new combination pharmaceutical-grade CBD and THC product to treat MS spasticity using Catalent’s orally disintegrating tablet technology.
FDA Warning Letter to Lupin Underscores the Need for Top Management Involvement in cGMP Compliance
October 17th 2019Over a two-year period, FDA inspections at company facilities found repeat problems with quality systems including lack of written procedures, inadequate investigation of out-of-specification conditions and corrective and preventive action, and insufficient cleaning and cleaning validation.
Avacta, ADC Therapeutics Enter Agreement for Development of Affimer-Drug Conjugates
October 10th 2019Biotechnology company, Avacta Group, and clinical-stage oncology-focused biotech, ADC Therapeutics, have entered into a collaboration and option agreement focused on the development of potent Affimer-drug conjugates.